Jack A.  Khattar net worth and biography

Jack Khattar Biography and Net Worth

Director of scPharmaceuticals
Jack A. Khattar is the founder of Supernus Pharmaceuticals (NASDAQ:SUPN) and has served as president and chief executive officer and director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including board member, president and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an executive officer and the chairman of the management committee at CIMA, a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe and the Middle East. He served as a director of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the board of directors of Prevacus, Inc., a privately-held pharmaceutical company. Mr. Khattar earned his degrees in Marketing, with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.

What is Jack A. Khattar's net worth?

The estimated net worth of Jack A. Khattar is at least $4.04 million as of February 2nd, 2023. Mr. Khattar owns 804,142 shares of scPharmaceuticals stock worth more than $4,036,793 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Khattar may own. Learn More about Jack A. Khattar's net worth.

How do I contact Jack A. Khattar?

The corporate mailing address for Mr. Khattar and other scPharmaceuticals executives is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. scPharmaceuticals can also be reached via phone at (617) 517-0730 and via email at [email protected]. Learn More on Jack A. Khattar's contact information.

Has Jack A. Khattar been buying or selling shares of scPharmaceuticals?

Jack A. Khattar has not been actively trading shares of scPharmaceuticals over the course of the past ninety days. Most recently, on Friday, December 3rd, Jack A. Khattar bought 5,000 shares of scPharmaceuticals stock. The stock was acquired at an average cost of $3.91 per share, with a total value of $19,550.00. Learn More on Jack A. Khattar's trading history.

Who are scPharmaceuticals' active insiders?

scPharmaceuticals' insider roster includes Jack Khattar (Director), and John Tucker (CEO). Learn More on scPharmaceuticals' active insiders.

Jack A. Khattar Insider Trading History at scPharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2021Buy5,000$3.91$19,550.00View SEC Filing Icon  
See Full Table

Jack A. Khattar Buying and Selling Activity at scPharmaceuticals

This chart shows Jack A Khattar's buying and selling at scPharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

scPharmaceuticals Company Overview

scPharmaceuticals logo
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $5.02
Low: $4.97
High: $5.16

50 Day Range

MA: $5.49
Low: $4.86
High: $6.22

2 Week Range

Now: $5.02
Low: $4.63
High: $12.75

Volume

110,060 shs

Average Volume

238,793 shs

Market Capitalization

$180.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08